|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Wild and mutant forms of p53 protein were evaluated in 197 B-CLL patients at diagnosis or before progression by an immunoenzymatic method in plasma using an anti-p53 monoclonal antibody.
|
15590397 |
2004 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
While efficacy of high-dose corticosteroids is excellent including responses in patients with bulky lymphadenopathy or those considered ultra high-risk CLL because of deletion and/or mutation of p53 gene, the duration of response is still unsatisfactory.
|
22616646 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
When we investigated the molecular mechanisms of this bad prognosis, we observed a reduction in the expression of 2 p53 target genes, <i>p21</i> and ∆<i>Np73</i>, in CLL primary cells transfected with <i>FANCA</i>.
|
31251079 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
When RS was compared to the preceding CLL-phase and with untransformed-CLL, RS presented a higher degree of methylation for genes possessing the H3K27me3 mark and PRC2 targets, as well as for gene targets of TP53 and RB1.
|
23961875 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.
|
23821658 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
AlteredExpression
|
disease |
LHGDN |
We studied 126 well-characterized CLL patients by direct sequencing and DHPLC to detect TP53 mutations (exons 2-11).
|
18689542 |
2008 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
We reviewed the efficacy of alemtuzumab in the treatment of 28 patients with refractory chronic lymphocytic leukemia (CLL) in whom p53 status was known.
|
16219582 |
2005 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We review studies in CLL which utilize the 17p deletion or TP53 mutations for prognostic stratification with specific focus on the technologies used for detection, the thresholds established for clinical significance, and the clinical contexts in which these alterations are identified.
|
30836431 |
2020 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
We report a customized gene panel assay based on multiplex long-PCR followed by third generation sequencing on nanopore technology (MinION), designed to analyze five frequently mutated genes in chronic lymphocytic leukemia (CLL): TP53, NOTCH1, BIRC3, SF3B1 and MYD88.
|
30087429 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
We previously showed that the Hsp90 inhibitor, SNX-7081, synergizes with and restores sensitivity to fludarabine nucleoside (2-FaraA) in human chronic lymphocytic leukemia (CLL) cells with lesions in the p53 pathway (Best OG, et al., Leukemia Lymphoma 53:1367-75, 2012).
|
26556860 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We performed a large mutation analysis of TP53 at four centers and characterized the pattern of TP53 mutations in CLL.
|
20861914 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We investigated the gene expression of five key cell cycle regulators: TP 53, c-Myc, cyclin D2, p21WAF1/CIP1 and p27KIP1, which primarily regulate the G1 phase of the cell cycle, or S-phase entry and ultimately control the proliferation and cell growth as well as their role in B-CLL progression.
|
21478095 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
We investigated the function of the p53 axis in primary CLL samples by studying p53 and p21 responses to irradiation by FACS and RT-PCR.
|
21115975 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
We identified driver mutations as predominantly clonal (e.g., MYD88, trisomy 12, and del(13q)) or subclonal (e.g., SF3B1 and TP53), corresponding to earlier and later events in CLL evolution.
|
23415222 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that ofatumumab with sequential methylprednisolone - alemtuzumab would be an effective and tolerable regimen for patients with high-risk chronic lymphocytic leukemia (CLL) with TP53 dysfunction.
|
30322319 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We have previously reported that p53 gene mutations were associated with aggressive B-CLL and a poor prognosis.
|
7949099 |
1994 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We have investigated the frequency of p53 mutations in B- and T-cell human lymphoid malignancies, including acute lymphoblastic leukemia, the major subtypes of non-Hodgkin lymphoma, and chronic lymphocytic leukemia. p53 exons 5-9 were studied by using genomic DNA from 197 primary tumors and 27 cell lines by single-strand conformation polymorphism analysis and by direct sequencing of PCR-amplified fragments.
|
2052620 |
1991 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
We found that the area under the curve (AUC) values of 8 miRNAs (miR-106a, miR-15a, miR-30a, miR-30b, miR-20a, miR-20b, miR-30d and miR-30e) and 8 mRNAs [axis inhibition protein 2 (AXIN2), integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) (ITGA3), tumor protein p53 inducible nuclear protein (TP53INP)1, TP53INP2, B-cell CLL/lymphoma 2 (BCL2), phosphatase and tensin homolog (PTEN), FOS and K(lysine) acetyltransferase 2B (KAT2B)] were >0.90.
|
26252081 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We found that any type of TP53 alteration was associated with very short telomeres and high hTERT expression, independently of other biological CLL features.
|
27486974 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We first performed detailed genetic analyses in a CLL cohort (n=110) containing ATM, SF3B1 and TP53 gene defects.
|
25371178 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the impact of TP53 mutations on clinical outcome by analyzing 98 untreated CLL using the AmpliChip p53 Research Test and direct sequencing and performed microarrays analysis on TP53 mutated and/or deleted cases.
|
21319261 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We conclude that progressive B-CLL is characterized by aberrant p53 expression which may be a significant prognostic factor.
|
8056442 |
1994 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
We conclude that CYC202 is a potent inducer of apoptosis in B-CLL regardless of the functional status of the p53 pathway, and may be considered as a therapeutic agent to improve the outcome of resistant B-CLL tumors.
|
15692065 |
2005 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We conclude that 1) FISH is a simple and sensitive technique for the detection of numerical and structural chromosome abnormalities; 2) Its application to uncultured samples obviates the alteration of results originated by the probable growth advantage of the normal or neoplastic cell population in vitro; 3) Trisomy 12 appears to define a B-CLL subgroup of atypical morphology; and 4) The p53 deletion is correlated with advanced stage of disease and resistance to treatment.
|
8830719 |
1996 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We carried out a mutation analysis of TP53 gene in 72 patients with CLL.
|
28476805 |
2017 |